altretamine has been researched along with Carcinoma, Anaplastic in 31 studies
Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A phase II study was performed of oral altretamine in 71 patients with ovarian carcinoma who entered clinical complete remission with CA125 levels less than 35 U/mL after initial or second-line chemotherapy, and relapsed more than 6 months later." | 9.08 | Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. ( Brown, S; Coleman, R; Crawford, M; Evans, H; Johnson, J; Lambert, HE; Ledermann, J; Nelstrop, AE; Oster, W; Rustin, GJ, 1997) |
| "In women with advanced ovarian cancer, initial therapy with a cisplatin-based combination chemotherapy regimen resulted in higher clinical complete response rates and longer time to failure compared with initial therapy with a single, oral alkylating agent; however, the benefits of this approach were confined to women older than 50 years of age at diagnosis, and there was no significant difference in survival." | 6.68 | Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. ( Carbone, P; Vogl, S; Wadler, S; Yeap, B, 1996) |
| "A phase II study was performed of oral altretamine in 71 patients with ovarian carcinoma who entered clinical complete remission with CA125 levels less than 35 U/mL after initial or second-line chemotherapy, and relapsed more than 6 months later." | 5.08 | Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. ( Brown, S; Coleman, R; Crawford, M; Evans, H; Johnson, J; Lambert, HE; Ledermann, J; Nelstrop, AE; Oster, W; Rustin, GJ, 1997) |
| "Fifty-seven evaluable patients with advanced ovarian carcinoma were randomized to receive either a combination of hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil (Hexa-CAF) or high-dose cyclophosphamide alone given intravenously intermittently." | 5.05 | Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF). ( Carmo-Pereira, J; Costa, FO; Henriques, E; Ricardo, JA, 1981) |
| "The human lung carcinoma MV522 cell line and its corresponding xenograft model were used to evaluate the activity of irofulven in combination with different DNA damaging agents." | 3.74 | Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. ( Estes, LA; Kelner, MJ; McMorris, TC; Rojas, RJ; Suthipinijtham, P, 2008) |
| "Hexamethylmelamine, mitomycin C and 5-fluorouracil infusion (HexMF) achieved a median survival of 9 months for the 45 patients with either metastatic stage III or unresectable stage II carcinoma of the pancreas." | 3.67 | Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion. ( Bruckner, HW; Butwell, N; Gorbaty, MI; Kalman, J; McKenna, A; Spigelman, M; Storch, J, 1989) |
| "In women with advanced ovarian cancer, initial therapy with a cisplatin-based combination chemotherapy regimen resulted in higher clinical complete response rates and longer time to failure compared with initial therapy with a single, oral alkylating agent; however, the benefits of this approach were confined to women older than 50 years of age at diagnosis, and there was no significant difference in survival." | 2.68 | Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. ( Carbone, P; Vogl, S; Wadler, S; Yeap, B, 1996) |
| "Epithelial ovarian cancer is usually diagnosed late in its biologic course (70% of cases are diagnosed as stage III or IV)." | 1.26 | Epithelial carcinoma of the ovary: current strategies. ( Kapp, DS; Katz, ME; Luikart, S; Schwartz, PE, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (70.97) | 18.7374 |
| 1990's | 7 (22.58) | 18.2507 |
| 2000's | 2 (6.45) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kelner, MJ | 1 |
| McMorris, TC | 1 |
| Rojas, RJ | 1 |
| Estes, LA | 1 |
| Suthipinijtham, P | 1 |
| Carmo-Pereira, J | 1 |
| Costa, FO | 1 |
| Henriques, E | 1 |
| Ricardo, JA | 1 |
| Pino y Torres, JL | 1 |
| Bross, DS | 1 |
| Hernandez, E | 1 |
| Rosenshein, N | 1 |
| Klein, JL | 1 |
| Ettinger, DS | 1 |
| Leichner, PK | 1 |
| Order, SE | 1 |
| Bruntsch, U | 1 |
| Gallmeier, WM | 1 |
| Meerpohl, HG | 1 |
| Grigorova, TM | 1 |
| Vartanian, LG | 1 |
| Marenich, AF | 1 |
| Katz, ME | 1 |
| Schwartz, PE | 2 |
| Kapp, DS | 1 |
| Luikart, S | 1 |
| Greco, FA | 2 |
| Julian, CG | 1 |
| Richardson, RL | 1 |
| Burnett, L | 1 |
| Hande, KR | 1 |
| Oldham, RK | 1 |
| Frasci, G | 1 |
| Comella, G | 1 |
| Comella, P | 1 |
| Conforti, S | 1 |
| Mastrantonio, P | 1 |
| Zullo, F | 1 |
| Persico, G | 1 |
| Moore, DH | 1 |
| Valea, F | 1 |
| Crumpler, LS | 1 |
| Fowler, WC | 1 |
| McGuire, WP | 1 |
| Wadler, S | 1 |
| Yeap, B | 1 |
| Vogl, S | 1 |
| Carbone, P | 1 |
| Rustin, GJ | 1 |
| Nelstrop, AE | 1 |
| Crawford, M | 1 |
| Ledermann, J | 1 |
| Lambert, HE | 1 |
| Coleman, R | 1 |
| Johnson, J | 1 |
| Evans, H | 1 |
| Brown, S | 1 |
| Oster, W | 1 |
| Gershanovich, ML | 1 |
| Livshits, ME | 1 |
| Antipenkova, VI | 1 |
| Gad-el-Mawla, NM | 1 |
| Muggia, FM | 1 |
| Hamza, MR | 1 |
| El-Morsi, B | 1 |
| Sherif, M | 1 |
| Mansour, MA | 1 |
| Khafagy, M | 1 |
| El-Sebai, IT | 1 |
| Krauss, S | 1 |
| Tornyos, K | 1 |
| DeSimone, P | 1 |
| Lowenbraun, S | 1 |
| McKeown, J | 1 |
| Solomon, A | 1 |
| Sonoda, T | 1 |
| Omura, GA | 1 |
| Brady, MF | 1 |
| Homesley, HD | 1 |
| Yordan, E | 1 |
| Major, FJ | 1 |
| Buchsbaum, HJ | 1 |
| Park, RC | 1 |
| Lund, B | 1 |
| Hansen, M | 1 |
| Hansen, HH | 1 |
| Thomsen, HK | 1 |
| Sørensen, BL | 1 |
| Nielsen, NC | 1 |
| Lundvall, F | 1 |
| Sipilä, P | 1 |
| Kivinen, S | 1 |
| Gröhn, P | 1 |
| Vesala, J | 1 |
| Heinonen, E | 1 |
| Bruckner, HW | 1 |
| Kalman, J | 1 |
| Spigelman, M | 1 |
| Gorbaty, MI | 1 |
| Butwell, N | 1 |
| Storch, J | 1 |
| McKenna, A | 1 |
| Rizel, S | 2 |
| Biran, S | 2 |
| Anteby, SO | 1 |
| Brufman, G | 1 |
| Sulkes, A | 1 |
| Milwidsky, A | 1 |
| Weshler, Z | 1 |
| Fuks, Z | 2 |
| Belinson, JL | 1 |
| Pretorius, RG | 1 |
| McClure, M | 1 |
| Ashikaga, T | 1 |
| de Gramont, A | 1 |
| Drolet, Y | 1 |
| Louvet, C | 1 |
| Dray, C | 1 |
| Krulik, M | 1 |
| Pigné, A | 1 |
| Lavoie, A | 1 |
| Painchaud, M | 1 |
| Blouin, R | 1 |
| Tessier, C | 1 |
| Laufman, LR | 1 |
| Green, JB | 1 |
| Alberts, DS | 1 |
| O'Toole, R | 1 |
| Hilgers, RD | 1 |
| Young, DC | 1 |
| Lin, F | 1 |
| Rivkin, SE | 1 |
| Keating, G | 1 |
| Kohorn, EI | 1 |
| Chambers, JT | 1 |
| Wu, BZ | 1 |
| Neijt, JP | 1 |
| ten Bokkel Huinink, WW | 1 |
| van der Burg, ME | 1 |
| van Oosterom, AT | 2 |
| Willemse, PH | 1 |
| Heintz, AP | 2 |
| van Lent, M | 1 |
| Trimbos, JB | 2 |
| Bouma, J | 1 |
| Vermorken, JB | 1 |
| Hainsworth, JD | 1 |
| Grosh, WW | 1 |
| Burnett, LS | 1 |
| Jones, HW | 1 |
| Wolff, SN | 1 |
| Schaberg, A | 1 |
| Van der Velde, EA | 1 |
| Nooy, M | 1 |
| Fuller, AF | 1 |
| Krane, IM | 1 |
| Budzik, GP | 1 |
| Donahoe, PK | 1 |
2 reviews available for altretamine and Carcinoma, Anaplastic
| Article | Year |
|---|---|
[Chemotherapy of advanced epithelial ovarian carcinoma].
Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 1984 |
Primary treatment of epithelial ovarian malignancies.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 1993 |
12 trials available for altretamine and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Antineoplastic Agents; Carcinoma; Clinical Trial | 1981 |
Multimodality treatment of patients with advanced ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Altretamine; Antibodies, Neoplasm; Carcinoma; Cisplatin; Clinical Trials a | 1982 |
Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study.
Topics: Administration, Oral; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 1995 |
Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Car | 1996 |
Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Agents, Alkylating | 1997 |
Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26.
Topics: Adolescent; Adult; Aged; Altretamine; Carcinoma; Carcinoma, Squamous Cell; Clinical Trials as Topic; | 1978 |
cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lung cancer: a pilot study of the Southeastern Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical T | 1979 |
Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.
Topics: Adult; Aged; Altretamine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carc | 1991 |
A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cycl | 1990 |
Chemotherapy of drug-resistant ovarian cancer: a Southwest Oncology Group Study.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clin | 1986 |
CHAP II therapy for epithelial ovarian cancers following primary treatment with platinum-based combination chemotherapy.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clin | 1986 |
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma; Cispla | 1987 |
17 other studies available for altretamine and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Topics: Altretamine; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc | 2008 |
[Chemotherapy of epithelial ovarian carcinoma].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chlorambucil; Cisplatin; Cyc | 1983 |
[Surgical method and combination chemotherapy in treating stage-III and IV ovarian cancer].
Topics: Altretamine; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Evaluati | 1980 |
Epithelial carcinoma of the ovary: current strategies.
Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Carcinoma; Cisplatin; Doxorubicin; Drug Thera | 1981 |
Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin | 1981 |
Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Carcinoma; Female; Humans; Middle Aged; Neoplasm Recurr | 1993 |
[Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma].
Topics: Adult; Aged; Altretamine; Antineoplastic Agents, Alkylating; Carcinoma; Chemotherapy, Adjuvant; Drug | 2000 |
Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma.
Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carc | 1989 |
Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluorouracil; Humans; Infusi | 1989 |
Combined modality treatment for stage III ovarian carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Antineoplastic Combined Chemothe | 1985 |
Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modali | 1986 |
[Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; | 1986 |
[Chemotherapy of epithelial ovarian cancer: CHexUP versus thio-tepa].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; | 1987 |
Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cycl | 1988 |
Chemotherapeutic and surgical induction of pathological complete remission and whole abdominal irradiation for consolidation does not enhance the cure of stage III ovarian carcinoma.
Topics: Abdomen; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispla | 1988 |
The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1988 |
Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.
Topics: Adenocarcinoma; Altretamine; Anti-Mullerian Hormone; Ascitic Fluid; Carcinoma; Chromatography, Affin | 1985 |